103 related articles for article (PubMed ID: 20738069)
1. Auger-mediated cytotoxicity of cancer cells in culture by an 125I-antisense oligomer delivered as a three-component streptavidin nanoparticle.
Liu X; Nakamura K; Wang Y; Cheng D; Liang M; Xiao N; Chen L; Rusckowski M; Hnatowich DJ
J Biomed Nanotechnol; 2010 Apr; 6(2):153-7. PubMed ID: 20738069
[TBL] [Abstract][Full Text] [Related]
2. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In.
Liu X; Wang Y; Nakamura K; Kawauchi S; Akalin A; Cheng D; Chen L; Rusckowski M; Hnatowich DJ
J Nucl Med; 2009 Apr; 50(4):582-90. PubMed ID: 19289423
[TBL] [Abstract][Full Text] [Related]
3. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery.
Liu X; Wang Y; Nakamura K; Kubo A; Hnatowich DJ
Cancer Gene Ther; 2008 Feb; 15(2):126-32. PubMed ID: 18084241
[TBL] [Abstract][Full Text] [Related]
4. Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation.
Liu Y; Cheng D; Liu X; Liu G; Dou S; Xiao N; Chen L; Rusckowski M; Hnatowich DJ
Nucl Med Biol; 2012 Jan; 39(1):101-7. PubMed ID: 21958854
[TBL] [Abstract][Full Text] [Related]
5. Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle.
Wang Y; Liu X; Chen L; Cheng D; Rusckowski M; Hnatowich DJ
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1977-86. PubMed ID: 19572130
[TBL] [Abstract][Full Text] [Related]
6. A nanoparticle for tumor targeted delivery of oligomers.
Liu X; Wang Y; Hnatowich DJ
Methods Mol Biol; 2011; 764():91-105. PubMed ID: 21748635
[TBL] [Abstract][Full Text] [Related]
7. Her2/neu small interfering RNA delivered in culture by a streptavidin nanoparticle.
Liu X; Nakamura K; Cheng D; Peng C; Xiao N; Liu Y; Chen L; Rusckowski M; Hnatowich DJ
Curr Drug Deliv; 2012 Jul; 9(4):431-6. PubMed ID: 22520071
[TBL] [Abstract][Full Text] [Related]
8. In vivo delivery of antisense MORF oligomer by MORF/carrier streptavidin nanoparticles.
Wang Y; Liu X; Nakamura K; Chen L; Rusckowski M; Hnatowich DJ
Cancer Biother Radiopharm; 2009 Oct; 24(5):573-8. PubMed ID: 19877887
[TBL] [Abstract][Full Text] [Related]
9. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.
Wang Y; Nakamura K; Liu X; Kitamura N; Kubo A; Hnatowich DJ
Bioconjug Chem; 2007; 18(4):1338-43. PubMed ID: 17605463
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
Costantini DL; Bateman K; McLarty K; Vallis KA; Reilly RM
J Nucl Med; 2008 Sep; 49(9):1498-505. PubMed ID: 18703606
[TBL] [Abstract][Full Text] [Related]
11. Molecular therapy of human neuroblastoma cells using Auger electrons of 111In-labeled N-myc antisense oligonucleotides.
Watanabe N; Sawai H; Ogihara-Umeda I; Tanada S; Kim EE; Yonekura Y; Sasaki Y
J Nucl Med; 2006 Oct; 47(10):1670-7. PubMed ID: 17015904
[TBL] [Abstract][Full Text] [Related]
12. Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells.
Cornelissen B; Hu M; McLarty K; Costantini D; Reilly RM
Nucl Med Biol; 2007 Jan; 34(1):37-46. PubMed ID: 17210460
[TBL] [Abstract][Full Text] [Related]
13. Radionuclide therapy using ¹³¹I-labeled anti-epidermal growth factor receptor-targeted nanoparticles suppresses cancer cell growth caused by EGFR overexpression.
Li W; Liu Z; Li C; Li N; Fang L; Chang J; Tan J
J Cancer Res Clin Oncol; 2016 Mar; 142(3):619-32. PubMed ID: 26573511
[TBL] [Abstract][Full Text] [Related]
14. Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers.
Liu P; Cai Z; Kang JW; Boyle AJ; Adams J; Lu Y; Ngo Ndjock Mbong G; Sidhu S; Reilly RM; Winnik MA
Biomacromolecules; 2014 Mar; 15(3):715-25. PubMed ID: 24506198
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.
Behr TM; Sgouros G; Vougiokas V; Memtsoudis S; Gratz S; Schmidberger H; Blumenthal RD; Goldenberg DM; Becker W
Int J Cancer; 1998 May; 76(5):738-48. PubMed ID: 9610734
[TBL] [Abstract][Full Text] [Related]
16. Targeting the human mdr1 gene by 125I-labeled triplex-forming oligonucleotides.
Sedelnikova OA; Panyutin IG; Luu AN; Reed MW; Licht T; Gottesman MM; Neumann RD
Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):443-52. PubMed ID: 11198928
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab Labeled to High Specific Activity with (111)In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells.
Ngo Ndjock Mbong G; Lu Y; Chan C; Cai Z; Liu P; Boyle AJ; Winnik MA; Reilly RM
Mol Pharm; 2015 Jun; 12(6):1951-60. PubMed ID: 25919639
[TBL] [Abstract][Full Text] [Related]
18. Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.
Malmberg J; Sandström M; Wester K; Tolmachev V; Orlova A
Nucl Med Biol; 2011 Nov; 38(8):1093-102. PubMed ID: 22137850
[TBL] [Abstract][Full Text] [Related]
19. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
Steinhauser IM; Langer K; Strebhardt KM; Spänkuch B
Biomaterials; 2008 Oct; 29(29):4022-8. PubMed ID: 18653231
[TBL] [Abstract][Full Text] [Related]
20. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
